Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CARL THORNBLADE

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1073605200
CMS profile
320358
Location
MISSOULA, MT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$2,537.19

102 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,537.19 102

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 3; records 101–102 of 102 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CARL THORNBLADE

NPI 1073605200 · CMS profile ID 320358

Allopathic & Osteopathic Physicians / Allergy & Immunology

MISSOULA, MT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–102 of 102 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1073605200?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CARL THORNBLADE, NPI 1073605200, CMS profile ID 320358. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–102 of 102 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073605200?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). CARL THORNBLADE, NPI 1073605200, CMS profile ID 320358. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–102 of 102 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073605200?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
CARL THORNBLADE, NPI 1073605200, CMS profile ID 320358, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–102 of 102 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1073605200?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

102 matching records · $2,537.19 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 102 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–102 of 102.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Blueprint Medicines Corporation $24.0701/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235822865 CMS
Regeneron Healthcare Solutions, Inc. $21.5501/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213058260 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,965.47 33
PY2020 $279.83 19
PY2021 $579.66 32
PY2022 $1,247.71 47
PY2023 $3,145.08 69
PY2024 $13,236.29 99
PY2025 $2,537.19 102

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $112,469.81 53
PY2024 Recipient $1,175.23 8
PY2024 Principal investigator $140,343.29 81
PY2023 Principal investigator $140,416.02 64
PY2022 Principal investigator $156,407.03 20
PY2021 Principal investigator $137,024.48 36
PY2020 Principal investigator $220,795.30 30
PY2019 Recipient $173.25 1
PY2019 Principal investigator $431,466.44 55

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

53 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $1,137.71 12/24/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192169911
Principal investigator 1 GlaxoSmithKline, LLC. $2,659.83 12/24/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192170339
Principal investigator 1 GlaxoSmithKline, LLC. $1,388.81 12/11/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192170331
Principal investigator 1 GlaxoSmithKline, LLC. $900.00 12/09/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN No dispute reported 06/30/2026 1192169915
Principal investigator 1 GlaxoSmithKline, LLC. $6,072.96 10/23/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192169923
Principal investigator 1 GlaxoSmithKline, LLC. $1,773.22 08/27/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192169927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $124.00 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222578
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $228.15 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222580
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222582
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $124.00 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222584
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $228.15 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222586
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222588
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $124.00 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222590
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $124.00 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222592
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $228.15 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222594
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222596
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $124.00 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222598
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $228.15 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222600
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222602
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222604
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222606
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $124.00 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222608
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $124.00 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222610
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $228.15 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222612
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $641.25 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222614
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.05 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222616
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222618
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222620
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $124.00 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222622
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $228.15 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222624
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222626
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $124.00 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222628
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $228.15 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222630
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $641.25 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222632
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222634
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $57.00 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222636
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $124.00 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222638
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $124.00 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222640
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $228.15 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222642
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $641.25 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222644
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.05 07/31/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184222646
Principal investigator 1 GlaxoSmithKline, LLC. $365.18 07/22/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192169919
Principal investigator 1 Blueprint Medicines Corporation $11,000.00 06/19/2025 Non-covered Recipient Entity
Montana Medical Research, Inc.
BLU-808-1201 No dispute reported 06/30/2026 1235785665
Principal investigator 1 SANOFI US SERVICES INC. $6,750.00 06/16/2025 Non-covered Recipient Entity
Elias Research Associates LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1226137515
Principal investigator 1 GlaxoSmithKline, LLC. $2,659.83 05/22/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192169932
Principal investigator 1 GlaxoSmithKline, LLC. $243.80 05/01/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH
A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP BAYESIAN No dispute reported 06/30/2026 1192170344
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,535.00 04/23/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184186625
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,000.00 04/23/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184186629
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,500.00 04/23/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184186631
Principal investigator 1 GlaxoSmithKline, LLC. $6,323.40 03/20/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192170327
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,998.16 02/26/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1185552159
Principal investigator 1 GlaxoSmithKline, LLC. $10,216.17 01/30/2025 Non-covered Recipient Entity
MONTANA MEDICAL RESEARCH
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192170335
Principal investigator 1 AstraZeneca Pharmaceuticals LP $26,873.69 01/22/2025 Non-covered Recipient Entity
ELIAS RESEARCH ASSOCIATES LLC
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1185552161